US23345J1043 - Common Stock
DICE Therapeutics Inc
NASDAQ:DICE (8/8/2023, 8:37:47 PM)
After market: 47.59 +0.04 (+0.08%)47.55
+0.03 (+0.06%)
DiCE Therapeutics, Inc. is a biopharmaceutical company, which designs and develops a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company is headquartered in South San Francisco, California and currently employs 81 full-time employees. The company went IPO on 2021-09-15. The firm is focused on developing oral therapeutics against well-validated targets in immunology. The firm's platform, DELSCAPE, is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs). The firm's therapeutic candidate, DC-806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. The firm is also developing oral therapeutic candidates targeting a4B7 integrin for the treatment of inflammatory bowel disease (IBD) and evaluating oral therapeutic candidates targeting aVB1/aVB6 integrin for the treatment of fibrosis.
DICE Therapeutics Inc
400 East Jamie Court, Suite 300
South San Francisco CALIFORNIA
P: 16505661402.0
CEO: J. Kevin Judice
Employees: 81
Website: https://www.dicetherapeutics.com/
Stifel has downgraded Morphic (MORF) to hold, stating that it believes open-label data for its drug candidate MORF-057 is not enough to score a near-term takeover deal. Read more.
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The...
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...
Here you can normally see the latest stock twits on DICE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: